Back to News
Market Impact: 0.25
What Corvus Pharmaceuticals (CRVS) Said on Its Q3 Earnings Call
Source: marketbeat.com
Corporate EarningsHealthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
Corvus Pharmaceuticals reported a wider third-quarter loss as clinical-trial spending increased. Executives outlined a series of milestones for lead experimental drug soquelitinib in 2027.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.15
Ticker Sentiment
CRVS-0.20
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook